INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) said Thursday that its neutralizing antibody Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among
“Of course, we didn’t put Democrats in the vial; we didn’t put Republicans in the vial,” University of Washington’s Dr. Larry Corey writes in a recent COVID-19 Vaccine Matters blog jointly produced by Johns Hopkins University and the UW. While development of vaccines now being distributed to combat COVID-19, the deadly disease caused by the novel coronavirus, are a “remarkable achievement” that demonstrate the power of science to save lives, mistrust and fear continue to cause nearly 40% of Americans to say they would be unlikely to get vaccinated. Larry Corey Some of that mistrust stems from before the pandemic, but unfortunate politicization of COVID-19 vaccine development is also to blame. When the current administration jumped in to claim credit for the rapid development of the vaccines, that act personalized the science behind its creation.
January 6, 2021
Researchers at the
University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company Novavax, Inc., based in Gaithersburg, MD.
Clockwise from top left: Monica McArthur, Karen Kotloff, E. Albert Reece, and Kathleen Neuzil.
The vaccine trial is being conducted by researchers in UMSOM’s
Center for Vaccine Development and Global Health (CVD) as part of their National Institute of Allergy and Infectious Diseases (NIAID)-funded Vaccine Treatment and Evaluation Unit (VTEU), and the COVID-19 Prevention Network (CoVPN). It adds to the extensive COVID-19 vaccine research that has been underway on campus since early spring.